Head-to-head · WeighScore
CoreAge Rx vs Gala Health
The verdict
CoreAge Rx takes it — 94/100 to 86/100.
CoreAge Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
CoreAge Rx is also our overall #1 pick — it tops the full scorecard at 94/100 (A).
Assume any provider we list may compensate us — we may earn a commission at no cost to you. It never changes the WeighScore.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | CoreAge Rx | Gala Health |
|---|---|---|
| WeighScore | 94/100 | 86/100 |
| Grade | A | B |
| Scorecard rank | #1 | #8 |
| Semaglutide | $149/mo | Not disclosed |
| Tirzepatide | $349/mo | $179/mo |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #1 · A
Strengths
- Flat all-in price with no month-two step-up
- Semaglutide and tirzepatide on one account
- All 50 states, LegitScript-verified
Where it loses points
- Not the cheapest sticker price
- Compounded only
- Pharmacy partner not yet publicly named
Graded #8 · B
Strengths
- Low compounded entry — tirzepatide $179/mo, microdose from $149, 3-month plans from $199
- Available in all 50 states
- Keeps a brand-name path open (Ozempic listed at $1,299)
- HRT and menopause care available alongside GLP-1
Where it loses points
- Compounded formulations are not FDA-approved
- Brand-name Ozempic is priced steeply at $1,299
- No oral or sublingual route offered yet
- Newer operator (Gala GLP-1 by AI Coaching Inc) with a shorter public record
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.